BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 1, 2015
View Archived Issues
Servier discloses novel Bcl-2 antagonists
Read More
Teijin Pharma reports development of novel xanthine oxidase inhibitors
Read More
Janssen discloses FLAP inhibitors
Read More
Bayer discloses BRD4 inhibitors
Read More
Takeda presents OX1 receptor antagonists
Read More
Bristol-Myers Squibb patents HIV integrase inhibitors
Read More
Lundbeck divulges BACE1 inhibitors
Read More
Neurons in Alzheimer's brains respond to nerve growth factor
Read More
Incyte discloses LSD1 inhibitors
Read More
Bayer expands finerenone program with three phase III studies
Read More
Ono Pharmaceuticals presents novel autotaxin inhibitors
Read More
Bionomics to begin phase I trial of BNC-101
Read More
Seikagaku terminates license agreement with Can-Fite BioPharma for RA product
Read More
Hisamitsu Pharmaceutical begins phase II study of HP-3150 in Japan
Read More
Eisai and Purdue to codevelop insomnia candidate lemborexant
Read More
ALK's house dust mite allergy immunotherapy approved in 11 European countries
Read More
Kanuma becomes first approved treatment in E.U. for LAL-D
Read More
FDA grants priority review to Intercept's NDA for obeticholic acid for primary biliary cirrhosis
Read More
Probuphine NDA resubmitted to FDA
Read More
First oral agent for Gaucher's disease launched in Japan
Read More
Initial results reported from phase I trial of RNAi therapeutic ALN-PCSsc
Read More
Dabrafenib-trametinib combination approved in the E.U. for BRAF V600 mutation-positive melanoma
Read More
Bristol-Myers Squibb gains exclusive right to acquire Promedior
Read More
Valeant licenses rights to brodalumab from AstraZeneca
Read More
European approval of Strensiq for pediatric-onset hypophosphatasia
Read More
Lipocine files U.S. NDA for testosterone replacement therapy LPCN-1021
Read More
Asahi Kasei announces launch date for Xiaflex in Japan
Read More